You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
PF 06726304 acetate
Biological Activity for PF 06726304 acetate
PF 06726304 acetate is a highly potent and SAM-competitive EZH2 lysine methyltransferase inhibitor (IC50 = 0.7 nM). Inhibits proliferation of Karpas-422 cells (non-Hodgkin's lymphoma) in vitro, and halts tumor growth and reduces intratumoral H3K27Me3 levels in mice.
Sold for research purposes under agreement from Pfizer Inc.
Technical Data for PF 06726304 acetate
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for PF 06726304 acetate
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for PF 06726304 acetate
The following data is based on the product molecular weight 506.38. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.97 mL||9.87 mL||19.75 mL|
|5 mM||0.39 mL||1.97 mL||3.95 mL|
|10 mM||0.2 mL||0.99 mL||1.97 mL|
|50 mM||0.04 mL||0.2 mL||0.39 mL|
Product Datasheets for PF 06726304 acetate
References for PF 06726304 acetate
References are publications that support the biological activity of the product.
Kung et al (2016) Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of zeste homolog 2 (EZH2) inhibitors. J.Med.Chem. 59 8306 PMID: 27512831
If you know of a relevant reference for PF 06726304 acetate, please let us know.
View Related Products by Product Action
Keywords: PF 06726304 acetate, PF 06726304 acetate supplier, PF06726304, acetate, highly, potent, EZH2, inhibitors, inhibits, enhancer, of, zeste, homolog, 2, lysine, methyltransferase, PRC2, polycomb, repressive, complex, Lysine, Methyltransferases, 6169, Tocris Bioscience
Citations for PF 06726304 acetate
Citations are publications that use Tocris products.
Currently there are no citations for PF 06726304 acetate. Do you know of a great paper that uses PF 06726304 acetate from Tocris? Please let us know.
Reviews for PF 06726304 acetate
There are currently no reviews for this product. Be the first to review PF 06726304 acetate and earn rewards!
Have you used PF 06726304 acetate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Stem Cells Scientific Review
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.